June 17, 2020 – CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced that the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Belgium. First subjects will be vaccinated at the Institute for Tropical Medicine in Tübingen and the Ghent University Hospital (Belgium), the Tropical Institute of the University Hospital Munich, LMU (Germany), and the Hannover Medical School (Germany).
CureVac´s mRNA vaccine candidate utilizes nucleotides without chemical modifications in the mRNA and is designed to provide a strong and balanced activation of the immune system. The mRNA encodes the full-length spike protein of SARS-CoV-2 and is formulated with lipid nanoparticles (LNP).
The vaccine project began in early 2020 and initially focused on characterization of several potential candidates that then led to the selection of the final candidate, termed CVnCoV. This thorough selection process was based on humoral and cellular immunogenicity data, a balanced immune-response as well as speed and capability for large scale manufacturing.
The Phase 1 dose escalation clinical trial will include 168 healthy subjects between the ages of 18 to 60 and will target a dose range of 2 µg to 8 µg. Aim is to determine the optimal dose as well as to evaluate the safety and immune profile of the vaccine in humans.
“We are encouraged that we received green light from the regulatory authorities to start the clinical development of our COVID-19 candidate. During the last few months our team has put a lot of efforts into the preclinical validation of several vaccine candidates to select an optimal construct. We are confident that our early optimization work will provide a safe and effective low dose vaccine. In parallel, we are already producing large quantities of this trial medication under GMP conditions,” says acting CEO of CureVac, Dr. Franz-Werner Haas.
Trial will start promptly and will be conducted in Germany and Belgium
The only product in the world to contain 8 special nutrients in the exact amounts scientifically proven to improve deep-sleep and enhance natural metabolic regeneration in both women and men. Burning fat, restoring your health, and turning back the clock simply could not be easier or more automatic.